4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow imagabalin: new trials by email Literature Review of imagabalin trials Research Report on imagabalin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) PD 0332334 - Generalized Anxiety Disorder | Phase 3 | Terminated | Pfizer | 468 | 2008-10-01 | 2012-11-16 |
| A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) PD 0332334, Paroxetine, Placebo - Generalized Anxiety Disorder | Phase 3 | Terminated | Pfizer | 360 | 2008-05-01 | 2012-11-16 |
| A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) PD 0332334, paroxetine, Placebo - Generalized Anxiety Disorder | Phase 3 | Terminated | Pfizer | 286 | 2008-05-01 | 2012-11-16 |
| A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) PD 0332334, Paroxetine, Placebo - Generalized Anxiety Disorder | Phase 3 | Terminated | Pfizer | 501 | 2008-04-01 | 2012-11-16 |
Generalized Anxiety Disorder (4)
Pfizer (4)
United States (4) · Hungary (3) · Russia (2) · Italy (1) · South Korea (1) · Taiwan (1)